Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients

BACKGROUND: Clinical trials assessing the combination therapy of metformin plus dipeptidyl peptidase-4 inhibitors versus metformin plus Sulfonylureas on risk of cardiovascular disease, cardiovascular mortality and/or all-cause mortality in type 2 diabetes have shown conflicting results. We therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fei, He, Yuan, Zhang, Rong, Zeng, Qiang, Zhao, Xiaolan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393015/
https://www.ncbi.nlm.nih.gov/pubmed/28885325
http://dx.doi.org/10.1097/MD.0000000000007638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393015/
https://www.ncbi.nlm.nih.gov/pubmed/28885325
http://dx.doi.org/10.1097/MD.0000000000007638

Ejemplares similares